Abion Inc.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Oct 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Data processing, analysis method of gene expression data to identify endogenous reference genes (US 10,304,561) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Mar 19, 2027The maintenance fee for PEGylated interferon-beta variant (US 11,759,500) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Reagent for detecting cross contamination of PDX-model related with human and mouse, the kit comprising the same, and the method for the cross contamination detection (US 10,472,678) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Jul 21, 2027The maintenance fee for Polymorphic forms of triazolopyrazine derivatives and method of preparing the same (US 10,538,529) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 1 fee due Sep 3, 2027The maintenance fee for Immune conjugate having dendron conjugated to antibody and use thereof (US 10,576,158) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for Camsylate salts of triazolopyrazine derivatives (US 11,964,979) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,425,906 | Method to Inhibit Cancer Targeting CD24 In force · High confidence | In force | High confidence | |
| US 8,101,716 | Human interferon-beta mutein In force · From the USPTO record | In force | From the USPTO record | |
| US 10,304,561 | Data processing, analysis method of gene expression data to identify endogenous reference genes In force · From the USPTO record | In force | From the USPTO record | |
| US 9,639,660 | Data Processing, Analysis Method of Gene Expression Data to Identify Endogenous Reference Genes In force · Medium confidence | In force | Medium confidence | |
| US 9,751,941 | Antigen derived from extracellular domain of multi-transmembrane protein and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,759,500 | PEGylated interferon-beta variant In force · From the USPTO record | In force | From the USPTO record | |
| US 10,576,158 | Immune conjugate having dendron conjugated to antibody and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,806,799 | Human interferon-beta variant conjugated immunocytokine and method for preparing same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,472,678 | Reagent for detecting cross contamination of PDX-model related with human and mouse, the kit comprising the same, and the method for the cross contamination detection In force · From the USPTO record | In force | From the USPTO record | |
| US 10,538,529 | Polymorphic forms of triazolopyrazine derivatives and method of preparing the same In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 22: 4 patents in force now held by others · 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 4 abandoned · 3 no status recorded